Bacteriophages for treatment of tuberculosis
Summary
USPTO granted Patent US12589127B2 to the University of Pittsburgh for pharmaceutical compositions comprising five or more bacteriophages designed to treat Mycobacterium tuberculosis infections. The patent covers methods of treating drug-resistant TB and preventing activation of latent TB disease, with 20 claims covering the phage combinations and treatment methods.
What changed
The USPTO issued Patent 12,589,127 B2 to University of Pittsburgh researchers Graham F. Hatfull, Carlos Andrés Guerrero, and Rebekah Marie Dedrick for bacteriophage-based therapeutic compositions. The patent claims pharmaceutical compositions combining five or more phages with a pharmaceutically acceptable carrier, along with methods for treating, reducing, or preventing diseases caused by M. tuberculosis, including antibiotic-resistant infections and activation of latent TB. The patent is classified under A61K 35/76 (pharmaceutical preparations containing viruses), A61P 31/06 (anti-tuberculosis agents), and related CPC codes.
Entities developing bacteriophage therapies for tuberculosis or related infections should conduct freedom-to-operate analyses to assess potential infringement risks. Pharmaceutical companies and research institutions in the phage therapy space should review the patent claims for scope and consider licensing opportunities if developing similar technologies. No compliance deadlines or regulatory requirements are associated with this patent grant.
What to do next
- Conduct freedom-to-operate analysis for phage therapy TB programs
- Review patent claims for potential licensing or development opportunities
- Consult IP counsel regarding infringement risk assessment
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Bacteriophages for treatment of tuberculosis
Grant US12589127B2 Kind: B2 Mar 31, 2026
Assignee
University of Pittsburgh—Of the Commonwealth System of Higher Education
Inventors
Graham F. Hatfull, Carlos Andrés Guerrero, Rebekah Marie Dedrick
Abstract
Disclosed are pharmaceutical compositions comprising a combination of five or more phages and a pharmaceutically acceptable carrier, as well as methods of treating, reducing, or preventing a disease caused by Mycobacterium tuberculosis in a mammal, methods of treating an antibiotic resistant infection in a mammal, and methods of treating, reducing, or preventing activation of a latent disease caused by M. tuberculosis.
CPC Classifications
A61K 35/76 A61K 9/0019 A61K 9/0073 A61P 31/06 C12N 2795/10321 C12N 2795/10332 C12N 7/00
Filing Date
2024-05-23
Application No.
18673024
Claims
20
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.